Bio-Techne Corporation TECH
Verdict: Sell. Fair value $48.14 against a price of $63.04 on 5 Jan 2026, 24% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: GAAP Net Income plummeted from $0.29B in 2023 to $0.07B in 2025 (-75%) despite Revenue growth.... Large divergence between GAAP Net Income ($0.07B) and implied Adjusted EPS performance (approx.... Net Margin compressed significantly from ~25% in 2023 to ~6% in 2025..
Main risks
- Severe deterioration in GAAP Net Income (down ~75% from 2023 peak) leading to P/E >100x
- Negative ROIIC (-11.3%) indicates EBIT has contracted while Invested Capital expanded over the last 3 years
- ROIC of 5.0% is likely below WACC, suggesting value destruction on capital employed
- GAAP Net Income plummeted from $0.29B in 2023 to $0.07B in 2025 (-75%) despite Revenue growth...
- Large divergence between GAAP Net Income ($0.07B) and implied Adjusted EPS performance (approx...
- GAAP Net Income plummeted from $0.29B in 2023 to $0.07B in 2025 (-75%) despite Revenue growth ($1.14B to $1.22B).